Profil
Bruce A.
Sullenger is the founder of Regado Biosciences, Inc. founded in 2003, Argos Therapeutics, Inc. founded in 1997, and Basking Biosciences, Inc. founded in 2019 where he currently holds the title of Director.
Postes actifs de Bruce A. Sullenger
| Sociétés | Poste | Début |
|---|---|---|
Basking Biosciences, Inc.
 Basking Biosciences, Inc. BiotechnologyHealth Technology Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019. | Fondateur | 01/01/2019 |
Anciens postes connus de Bruce A. Sullenger
| Sociétés | Poste | Fin |
|---|---|---|
| ARGOS THERAPEUTICS, INC. | Fondateur | - |
Regado Biosciences, Inc.
 Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Health Technology |
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
Basking Biosciences, Inc.
Basking Biosciences, Inc. BiotechnologyHealth Technology Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019. | Health Technology |